6 results about "Membrane Transporters" patented technology

The application discloses an Escherichia coli transmembrane transporter gene and application thereof in vitamin B6 biosynthesis. The application weakens a vitamin B6 transporter gene coding in the Escherichia coli, and the ability of a genetically engineered strain to produce vitamin B6 is greatly improved, and the genetically engineered strain has great application and popularization value. In the best embodiment, the extracellular yield of vitamin B6 of the genetically engineered strain is increased by 33.7% compared with that of a wild type, and the effect is extremely remarkable.

The invention represents new hybrid compounds of two natural products sclareol and doxorubicin in the form of their conjugates. These compounds are in the form of conjugates, where doxorubicin and sclareol are covalently linked by a linker in a 1:1 molar ratio. The hybrids have shown to possess anticancer properties and are effective in treating resistant cancer cells that have P-glycoprotein membrane transporter, responsible for resistance to doxorubicin. The hybrids have been tested on different types of cell lines, including human glioblastoma, non-small cell lung carcinoma, and colorectal carcinoma. Also, a method for their preparation and their use in medical products or pharmaceutical preparations has been determined. The results of the study include the cytotoxic activity of single, combined, and conjugated compounds in pairs of sensitive and resistant cancer cells, with and without P-glycoprotein expression. The selectivity towards cancer cells was determined by comparing with commercially available normal human lung fibroblast cells. The study also investigated the nanoparticle nature of hybrid compounds, their intracellular localization and toxicity in vivo.

The invention discloses an aromatic compound transporter mutant and application thereof, and belongs to the technical field of bioengineering. The mutant is obtained by carrying out site-specific substitution on a key residue of a gated ring on the basis of an outer membrane transporter derived from Pseudomonas putida, and specifically comprises one or a combination of more of substitution of 120th phenylalanine into glycine, substitution of 121st leucine into glycine and substitution of 122nd glutamine into glycine, and the mutant is obtained by carrying out site-specific substitution on a key residue of a gated ring of the outer membrane transporter, so that the mutant is obtained, and the mutant is obtained by carrying out site-specific substitution on the key residue of the gated ring of the Pseudomonas putida derived from Pseudomonas putida derived from Pseudomonas putida derived from Pseudomonas putida derived from Pseudomonas putida. Preferably, a single mutant F120G, a double mutant F120G / L121G or a three mutant F120G / L121G / Q122G can be included, and conservative substitution derivation can be carried out on the basis of the F120G / L121G / Q122G. The mutant can be used for microbial efficient production and cell tolerance regulation of aromatic compounds according to physicochemical characteristics of a target product, and has important application value in green biological manufacturing, fermentation engineering and bioremediation.

The invention discloses an HlyA secretion system for increasing the secretion amount of substrate protein and a construction method and application thereof.The HlyA secretion system comprises a first component, a second component and a third component, the first component comprises an inner membrane transporter HlyB and a membrane interstitial adaptor protein HlyD, and the inner membrane transporter HlyB and the membrane interstitial adaptor protein HlyD are obtained by expressing modified hlyBD operons; according to the modified hlyBD operon, a nucleotide sequence for coding a hexa-polyhistidine tag is inserted behind an hlyD gene initiation codon in the hlyBD operon; and a second component: an outer membrane channel protein TolC derived from a host cell. According to the invention, the HlyD protein is specifically modified, so that the secretion amount of the HlyA secretion system to the substrate protein is obviously increased.

This invention discloses an aromatic compound transporter protein mutant and its applications, belonging to the field of bioengineering technology. The mutant is based on *Pseudomonas putida* (…). Pseudomonas putida The outer membrane transport protein derived from [a specific source] is obtained by site-directed substitution of key residues in its gating loop. Specifically, this includes replacing phenylalanine at position 120 with glycine, leucine at position 121 with glycine, and glutamine at position 122 with glycine, or one or more combinations thereof. Preferred mutants include single mutant F120G, double mutant F120G / L121G, or triple mutant F120G / L121G / Q122G, and conserved substitution derivatization can also be performed based on these mutants. These mutants can be used for the efficient microbial production and cell tolerance regulation of aromatic compounds, based on the physicochemical properties of the target product, and have significant application value in green biomanufacturing, fermentation engineering, and bioremediation.

The application provides application of cannabidiol in oligopeptide transporter inhibitors and belongs to the technical field of membrane transporter inhibitors. The application provides application of cannabidiol in preparation of oligopeptide transporter inhibitors, in particular, non-substrate oligopeptide transporter inhibitors. It is found that cannabidiol is a non-substrate oligopeptide transporter inhibitor and can specifically inhibit the uptake capacity of oligopeptide transporter to substrates.